Keros Therapeutics (KROS) Treasury Shares (2019 - 2026)

Keros Therapeutics' (KROS) quarterly Treasury Shares came in at $21.1 million in Q4 2025, up 2827.36% on a QoQ basis from $721700.0 in Q3 2025.

Keros Therapeutics (KROS) Treasury Shares (2019 - 2026) Analysis & Trends

Keros Therapeutics (KROS) has 1 years of Treasury Shares data on file, last reported at $384.6 million in Q4 2025.

Quarterly Treasury Shares changed N/A year-over-year to $21.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $21.1 million (changed N/A YoY) and the FY2025 annual result came in at $21.1 million, changed N/A from the prior year.
Treasury Shares steadied at $384.6 million in Q4 2025.
In the past five years, Treasury Shares ranged from a high of $21.1 million in Q4 2025 to a low of $721700.0 in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Treasury Shares (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	36.40 Mn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	-
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	-
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	8.96 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	-
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	2.72 Mn
10	Keros Therapeutics	217.61 Mn	-40.00 Mn	-	21.13 Mn

Download Data